International Clinical Trial: Iparomlimab and Tuvonralimab as first-line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion acore >= 50%: a prospective single-arm II phase clinical trial

Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127826) titled 'Iparomlimab and Tuvonralimab as first-line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion acore >= 50%: a prospective single-arm II phase clinical trial' on July 8.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The first affiliated hostipal of nanchang university

Condition: Locally advanced or metastatic non-small cell lung cancer

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-07-15

Target Sample Size: Iparomlimab and Tuvonralimab:30;

Countries of Recruitment: China

To know more, visit http...